The 2015 update from the USPSTF concluded that, given the strong evidence base for the previous recommendations, the indirect evidence path for HTN screening did not need updating.[30] For patients who are screened, estimates of the potential benefit of treatment can be improved both by carefully measuring the degree of blood pressure elevation and by assessing the contribution of other risk factors to global cardiovascular risk.[31-33] Since increasing age is related to greater incidence of HTN, and because lifetime risk of developing HTN is so high (reaching approximately 90% for octogenarians), it is sensible to screen periodically.[34] Multiple separate guidelines make recommendations for rescreening intervals, but none are evidence based. Although not included in the systematic evidence review conducted as part of this guideline update, and thus not considered in determining the strength of recommendation, a 2015 SR by the USPSTF identified 40 studies addressing rescreening interval and hypertensive incidence in screened normotensive persons (defined as blood pressure <140/90 mm Hg using office blood pressure measurements).[35] There were highly variable estimates of incident HTN ranging from 2.2-4.4% at one- year interval and 2.1-28.4% at five-year intervals. This confirms the recommendation that there is value to screening normotensive adults, but the evidence remains unclear as to what the optimal interval should be. As this is a Not Reviewed, Amended recommendation, the Work Group did not systematically review evidence related to this recommendation. Based on the assessment of the quality of the evidence put forth in the 2014 VA/DoD HTN CPG,[29,31-34] the Work Group s confidence in the quality of the evidence is moderate. The body of evidence had some limitations including different treatment goals/targets and confounders in the analysis. 